ondansetron has been researched along with Panic Disorder in 3 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentagastrin, a cholecystokinin (CCK) agonist, produces anxiety and panic in patients with panic disorder and social phobia." | 9.08 | Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. ( Geraci, M; McCann, UD; Morgan, CM; Murphy, DL; Post, RM; Slate, SO, 1997) |
| "Pentagastrin, a cholecystokinin (CCK) agonist, produces anxiety and panic in patients with panic disorder and social phobia." | 5.08 | Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. ( Geraci, M; McCann, UD; Morgan, CM; Murphy, DL; Post, RM; Slate, SO, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schneier, FR | 1 |
| Garfinkel, R | 1 |
| Kennedy, B | 1 |
| Campeas, R | 1 |
| Fallon, B | 1 |
| Marshall, R | 1 |
| O'Donnell, L | 1 |
| Hogan, T | 1 |
| Liebowitz, MR | 1 |
| McCann, UD | 1 |
| Morgan, CM | 1 |
| Geraci, M | 1 |
| Slate, SO | 1 |
| Murphy, DL | 1 |
| Post, RM | 1 |
| Dépôt, M | 1 |
| Merani, S | 1 |
| Bradwejn, J | 1 |
| Mukherjee, J | 1 |
| Caillé, J | 1 |
| Gutkowska, J | 1 |
| Caillé, G | 1 |
2 trials available for ondansetron and Panic Disorder
| Article | Year |
|---|---|
Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia.
Topics: Adult; Behavior; Female; Hemodynamics; Hormones; Humans; Interpersonal Relations; Male; Ondansetron; | 1997 |
Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men.
Topics: Administration, Oral; Adolescent; Adult; Anti-Anxiety Agents; Cholecystokinin; Double-Blind Method; | 1998 |
1 other study available for ondansetron and Panic Disorder
| Article | Year |
|---|---|
Ondansetron in the treatment of panic disorder.
Topics: Administration, Oral; Adult; Agoraphobia; Female; Humans; Male; Middle Aged; Ondansetron; Panic Diso | 1996 |